PATENT CLAIM ANALYSIS

Application Number: 16101882
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "375000"]

Abstract:
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

Claim (Index 20):
The method of  claim 19 , wherein the benzoxazole derivative is a compound of formula VI: or a pharmaceutically acceptable salt thereof, wherein: Y is selected from the group consisting of COOH, and OH; and R 1 , R 2  and R 3  are each independently selected from the group consisting of hydrogen, halo, OH, B(OH) 2  and CF 3 .

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14353459', '15448054', '15736826', '13830731', '15480139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8190097276460847
- 35 USC 102 Novelty (BERT): 0.6524465277145413
- Combined Prediction Score: 0.8023534076529303
- Mean Citation Score: 485.68719
- Max Citation Score: 735.84143
- Similarity Product: 566.6593781779372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test